Table of Contents Author Guidelines Submit a Manuscript
Journal of Nutrition and Metabolism
Volume 2011, Article ID 708183, 11 pages
http://dx.doi.org/10.1155/2011/708183
Review Article

Cancer Risk in Type 2 Diabetes Mellitus: Metabolic Links and Therapeutic Considerations

Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, OH 44195, USA

Received 23 November 2010; Revised 10 February 2011; Accepted 24 March 2011

Academic Editor: Maria Luz Fernandez

Copyright © 2011 Grace Sun and Sangeeta R. Kashyap. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Czyzyk and Z. X. Szczepanik, “Diabetes mellitus and cancer,” European Journal of Internal Medicine, vol. 11, no. 5, pp. 245–252, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. “National Information Diabetes Clearinghouse. National Diabetes Statistics,” 2007, http://diabetes.niddk.nih.gov/dm/pubs/statistics/.
  3. American Cancer Society, “Cancer Facts and Figures,” 2009, http://www.cancer.org/Research/CancerFactsFigures/cancer-facts-figures-2009.
  4. American Diabetes Association, http://www.diabetes.org/diabetes-basics/diabetes-statistics/.
  5. E. Giovannucci, D. M. Harlan, M. C. Archer et al., “Diabetes and cancer: a consensus report,” CA Cancer Journal for Clinicians, vol. 60, no. 4, pp. 207–221, 2010. View at Publisher · View at Google Scholar
  6. W. Levine, A. R. Dyer, R. B. Shekelle, J. A. Schoenberger, and J. Stamler, “Post-load plasma glucose and cancer mortality in middle-aged men and women. 12-year follow-up findings of the Chicago Heart Association Detection Project in Industry,” American journal of epidemiology, vol. 131, no. 2, pp. 254–262, 1990. View at Google Scholar · View at Scopus
  7. L. S. A. Augustin, S. Gallus, S. Franceschi et al., “Glycemic index and load and risk of upper aero-digestive tract neoplasms (Italy),” Cancer Causes and Control, vol. 14, no. 7, pp. 657–662, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. A. Baron, E. Weiderpass, P. A. Newcomb et al., “Metabolic disorders and breast cancer risk (United States),” Cancer Causes and Control, vol. 12, no. 10, pp. 875–880, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. S. S. Coughlin, E. E. Calle, L. R. Teras, J. Petrelli, and M. J. Thun, “Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults,” American Journal of Epidemiology, vol. 159, no. 12, pp. 1160–1167, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. L. L. Lipscombe, P. J. Goodwin, B. Zinman, J. R. McLaughlin, and J. E. Hux, “Diabetes mellitus and breast cancer: a retrospective population-based cohort study,” Breast Cancer Research and Treatment, vol. 98, no. 3, pp. 349–356, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. K. B. Michels, C. G. Solomon, F. B. Hu et al., “Type 2 diabetes and subsequent incidence of breast cancer in the nurses' health study,” Diabetes Care, vol. 26, no. 6, pp. 1752–1758, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Friberg, N. Orsini, C. S. Mantzoros, and A. Wolk, “Diabetes mellitus and risk of endometrial cancer: a meta-analysis,” Diabetologia, vol. 50, no. 7, pp. 1365–1374, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. K. E. Anderson, E. Anderson, P. J. Mink et al., “Diabetes and endometrial cancer in the Iowa Women's Health Study,” Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 6, pp. 611–616, 2001. View at Google Scholar · View at Scopus
  14. R. Talamini, S. Franceschi, A. Favero, E. Negri, F. Parazzini, and C. La Vecchia, “Selected medical conditions and risk of breast cancer,” British Journal of Cancer, vol. 75, no. 11, pp. 1699–1703, 1997. View at Google Scholar · View at Scopus
  15. E. Weiderpass, G. Gridley, I. Persson, O. Nyrén, A. Ekbom, and H. O. Adami, “Risk of endometrial and breast cancer in patients with diabetes mellitus,” International Journal of Cancer, vol. 71, no. 3, pp. 360–363, 1997. View at Google Scholar · View at Scopus
  16. L. Wideroff, G. Gridley, L. Mellemkjaer et al., “Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in denmark,” Journal of the National Cancer Institute, vol. 89, no. 18, pp. 1360–1365, 1997. View at Google Scholar · View at Scopus
  17. J. Yun, C. Rago, I. Cheong et al., “Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells,” Science, vol. 325, no. 5947, pp. 1555–1559, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Vigneri, F. Frasca, L. Sciacca, G. Pandini, and R. Vigneri, “Diabetes and cancer,” Endocrine-Related Cancer, vol. 16, no. 4, pp. 1103–1123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. HA. J. Sun, H. Ohrr, W. S. Jae, E. Y. Ji, M. Ji, and J. M. Samet, “Fasting serum glucose level and cancer risk in Korean men and women,” Journal of the American Medical Association, vol. 293, no. 2, pp. 194–202, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Inoue, M. Iwasaki, T. Otani, S. Sasazuki, M. Noda, and S. Tsugane, “Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan,” Archives of Internal Medicine, vol. 166, no. 17, pp. 1871–1877, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. B. B. Barone, H. C. Yeh, C. F. Snyder et al., “Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis,” Journal of the American Medical Association, vol. 300, no. 23, pp. 2754–2764, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. X. Yang, G. T. C. Ko, W. Y. So et al., “Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry,” Diabetes, vol. 59, no. 5, pp. 1254–1260, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Steenland, S. Nowlin, and S. Palu, “Cancer incidence in the national health and nutrition survey I follow-up data: diabetes, cholesterol, pulse, and physical activity,” Cancer Epidemiology Biomarkers and Prevention, vol. 4, no. 8, pp. 807–811, 1995. View at Google Scholar · View at Scopus
  24. T. P. Ciaraldi and T. Sasaoka, “Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities,” Hormone and Metabolic Research, vol. 43, no. 1, pp. 1–10, 2011. View at Publisher · View at Google Scholar
  25. A. Belfiore, F. Frasca, G. Pandini, L. Sciacca, and R. Vigneri, “Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease,” Endocrine Reviews, vol. 30, no. 6, pp. 586–623, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Cusi, K. Maezono, A. Osman et al., “Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle,” Journal of Clinical Investigation, vol. 105, no. 3, pp. 311–320, 2000. View at Google Scholar · View at Scopus
  27. S. G. Dann, A. Selvaraj, and G. Thomas, “mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer,” Trends in Molecular Medicine, vol. 13, no. 6, pp. 252–259, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. R. S. Ahima, “Metabolic actions of adipocyte hormones: focus on adiponectin,” Obesity, vol. 14, supplement 1, pp. 9S–15S, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. R. S. Ahima, “Central actions of adipocyte hormones,” Trends in Endocrinology and Metabolism, vol. 16, no. 7, pp. 307–313, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. P. J. Havel, “Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism,” Diabetes, vol. 53, no. 1, pp. S143–S151, 2004. View at Google Scholar · View at Scopus
  31. M. B. Jackson and R. S. Ahima, “Neuroendocrine and metabolic effects of adipocyte-derived hormones,” Clinical Science, vol. 110, no. 2, pp. 143–152, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Cusi, “The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes,” Current Diabetes Reports, vol. 10, pp. 306–315, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. C. M. Steppan, S. T. Bailey, S. Bhat et al., “The hormone resistin links obesity to diabetes,” Nature, vol. 409, no. 6818, pp. 307–312, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Wolf, S. Sadetzki, R. Catane, A. Karasik, and B. Kaufman, “Diabetes mellitus and breast cancer,” Lancet Oncology, vol. 6, no. 2, pp. 103–111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Sjöström, “Bariatric surgery and reduction in morbidity and mortality: experiences from the SOS study,” International Journal of Obesity, vol. 32, supplement 7, pp. S93–S97, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. H. A. Weiss, L. A. Brinton, N. A. Potischman et al., “Breast cancer risk in young women and history of selected medical conditions,” International Journal of Epidemiology, vol. 28, no. 5, pp. 816–823, 1999. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Hjalgrim, M. Frisch, A. Ekbom, K. O. Kyvik, M. Melbye, and A. Green, “Cancer and diabetes—a follow-up study of two population-based cohorts of diabetic patients,” Journal of Internal Medicine, vol. 241, no. 6, pp. 471–475, 1997. View at Google Scholar · View at Scopus
  38. C. La Vecchia, E. Negri, S. Franceschi, B. D'Avanzo, and P. Boyle, “A case-control study of diabetes mellitus and cancer risk,” British Journal of Cancer, vol. 70, no. 5, pp. 950–953, 1994. View at Google Scholar · View at Scopus
  39. P. J. Mink, E. Shahar, W. D. Rosamond, A. J. Alberg, and A. R. Folsom, “Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study,” American Journal of Epidemiology, vol. 156, no. 4, pp. 349–352, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. A. G. Renehan, M. Zwahlen, C. Minder, S. T. O'Dwyer, S. M. Shalet, and M. Egger, “Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis,” Lancet, vol. 363, no. 9418, pp. 1346–1353, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Wu, K. Cui, K. Miyoshi et al., “Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors,” Cancer Research, vol. 63, no. 15, pp. 4384–4388, 2003. View at Google Scholar · View at Scopus
  42. H. O. Adami, J. McLaughlin, A. Ekbom et al., “Cancer risk in patients with diabetes mellitus,” Cancer Causes and Control, vol. 2, no. 5, pp. 307–314, 1991. View at Publisher · View at Google Scholar · View at Scopus
  43. F. B. Hu, J. E. Manson, S. Liu et al., “Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women,” Journal of the National Cancer Institute, vol. 91, no. 6, pp. 542–547, 1999. View at Google Scholar · View at Scopus
  44. C. La Vecchia, E. Negri, A. Decarli, and S. Franceschi, “Diabetes mellitus and colorectal cancer risk,” Cancer Epidemiology Biomarkers and Prevention, vol. 6, no. 12, pp. 1007–1010, 1997. View at Google Scholar · View at Scopus
  45. S. C. Larsson, E. Giovannucci, and A. Wolk, “Diabetes and colorectal cancer incidence in the cohort of Swedish men,” Diabetes Care, vol. 28, no. 7, pp. 1805–1807, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. S. C. Larsson, N. Orsini, and A. Wolk, “Diabetes mellitus and risk of colorectal cancer: a meta-analysis,” Journal of the National Cancer Institute, vol. 97, no. 22, pp. 1679–1687, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Seow, J. M. Yuan, W. P. Koh, H. P. Lee, and M. C. Yu, “Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese health study,” Journal of the National Cancer Institute, vol. 98, no. 2, pp. 135–138, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. S. H. Saydah, C. M. Loria, M. S. Eberhardt, and F. L. Brancati, “Abnormal glucose tolerance and the risk of cancer death in the United States,” American Journal of Epidemiology, vol. 157, no. 12, pp. 1092–1100, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. T. I. L. Nilsen and L. J. Vatten, “Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis,” British Journal of Cancer, vol. 84, no. 3, pp. 417–422, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. T. O. Keku, P. K. Lund, J. Galanko, J. G. Simmons, J. T. Woosley, and R. S. Sandler, “Insulin resistance, apoptosis, and colorectal adenoma risk,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 9, pp. 2076–2081, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. R. Kaaks, P. Toniolo, A. Akhmedkhanov et al., “Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women,” Journal of the National Cancer Institute, vol. 92, no. 19, pp. 1592–1600, 2000. View at Google Scholar · View at Scopus
  52. R. Palmqvist, P. Stattin, S. Rinaldi et al., “Plasma insulin, IGF-binding proteins-1 and -2 and risk of colorectal cancer: a prospective study in Northern Sweden,” International Journal of Cancer, vol. 107, no. 1, pp. 89–93, 2003. View at Publisher · View at Google Scholar · View at Scopus
  53. S. H. Saydah, E. A. Platz, N. Rifai, M. N. Pollak, F. L. Brancati, and K. J. Helzlsouer, “Association of markers of insulin and glucose control with subsequent colorectal cancer risk,” Cancer Epidemiology Biomarkers and Prevention, vol. 12, no. 5, pp. 412–418, 2003. View at Google Scholar · View at Scopus
  54. A. B. De Gonzalez, E. Y. Ji, S. Y. Lee, A. P. Klein, and HA. J. Sun, “Pancreatic cancer and factors associated with the insulin resistance syndrome in the Korean cancer prevention study,” Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 2, pp. 359–364, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. J. A. Davila, R. O. Morgan, Y. Shaib, K. A. McGlynn, and H. B. El-Serag, “Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study,” Gut, vol. 54, no. 4, pp. 533–539, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. H. B. El-Serag, P. A. Richardson, and J. E. Everhart, “The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans,” American Journal of Gastroenterology, vol. 96, no. 8, pp. 2462–2467, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Fujino, T. Mizoue, N. Tokui, and T. Yoshimura, “Prospective study of diabetes mellitus and liver cancer in Japan,” Diabetes/Metabolism Research and Reviews, vol. 17, no. 5, pp. 374–379, 2001. View at Publisher · View at Google Scholar · View at Scopus
  58. M. M. Hassan, S. A. Curley, D. Li et al., “Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma,” Cancer, vol. 116, no. 8, pp. 1938–1946, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Kuper, A. Tzonou, E. Kaklamani et al., “Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma,” International Journal of Cancer, vol. 85, no. 4, pp. 498–502, 2000. View at Google Scholar · View at Scopus
  60. H. E. Kuper, A. Tzonou, E. Kaklamani et al., “Hepatitis B and C viruses in the etiology of hepatocellular carcinoma; a study in Greece using third-generation assays,” Cancer Causes and Control, vol. 11, no. 2, pp. 171–175, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. P. Lagiou, H. Kuper, S. O. Stuver, A. Tzonou, D. Trichopoulos, and H. O. Adami, “Role of diabetes mellitus in the etiology of hepatocellular carcinoma,” Journal of the National Cancer Institute, vol. 92, no. 13, pp. 1096–1099, 2000. View at Google Scholar · View at Scopus
  62. E. Giovannucci, E. B. Rimm, M. J. Stampfer, G. A. Colditz, and W. C. Willett, “Diabetes mellitus and risk of prostate cancer (United States),” Cancer Causes and Control, vol. 9, no. 1, pp. 3–9, 1998. View at Publisher · View at Google Scholar · View at Scopus
  63. D. Li and J. L. Abbruzzese, “New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts,” Clinical Cancer Research, vol. 16, no. 17, pp. 4313–4318, 2010. View at Publisher · View at Google Scholar
  64. D. Li, S. J. Yeung, M. M. Hassan, M. Konopleva, and J. L. Abbruzzese, “Antidiabetic therapies affect risk of pancreatic cancer,” Gastroenterology, vol. 137, no. 2, pp. 482–488, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. L. Gullo, R. Pezzilli, A. M. Morselli-Labate et al., “Italian Pancreatic Cancer Study Group. Diabetes and the risk of pancreatic cancer,” The New England Journal of Medicine, vol. 331, no. 2, pp. 81–84, 1994. View at Publisher · View at Google Scholar
  66. S. T. Chari, C. L. Leibson, K. G. Rabe et al., “Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer,” Gastroenterology, vol. 134, no. 1, pp. 95–101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. F. Wang, M. Herrington, J. Larsson, and J. Permert, “The relationship between diabetes and pancreatic cancer,” Molecular Cancer, vol. 2, article 4, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. F. Wang, J. Larsson, A. Abdiu et al., “Dissociated secretion of islet amyloid polypeptide and insulin in serum- free culture media conditioned by human pancreatic adenocarcinoma cell lines,” International Journal of Pancreatology, vol. 21, no. 2, pp. 157–164, 1997. View at Google Scholar · View at Scopus
  69. P. M. Webb, M. Law, C. Varghese, and D. Forman, “Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts,” Gut, vol. 49, no. 3, pp. 347–353, 2001. View at Publisher · View at Google Scholar
  70. S. Aydemir, T. Bayraktaroglu, M. Sert et al., “The effect of Helicobacter pylori on insulin resistance,” Digestive Diseases and Sciences, vol. 50, no. 11, pp. 2090–2093, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Yamagata, Y. Kiyohara, K. Aoyagi et al., “Impact of Helicobacter pylori infection on gastric cancer incidence in a general Japanese population: the Hisayama Study,” Archives of Internal Medicine, vol. 160, no. 13, pp. 1962–1968, 2000. View at Google Scholar · View at Scopus
  72. R. Gen, M. Demir, and H. Ataseven, “Effect of helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation,” Southern Medical Journal, vol. 103, no. 3, pp. 190–196, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. A. I. Adler, N. S. Weiss, M. L. Kamb, and J. L. Lyon, “Is diabetes mellitus a risk factor for ovarian cancer? A case-control study in Utah and Washington (United States),” Cancer Causes and Control, vol. 7, no. 4, pp. 475–478, 1996. View at Publisher · View at Google Scholar · View at Scopus
  74. C. Rodriguez, A. V. Patel, A. M. Mondul, E. J. Jacobs, M. J. Thun, and E. E. Calle, “Diabetes and risk of prostate cancer in a prospective cohort of US men,” American Journal of Epidemiology, vol. 161, no. 2, pp. 147–152, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Anzo, L. J. Cobb, D. L. Hwang et al., “Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression,” Cancer Research, vol. 68, no. 9, pp. 3342–3349, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. G. D. Smith, M. Egger, M. J. Shipley, and M. G. Marmot, “Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men,” American Journal of Epidemiology, vol. 136, no. 9, pp. 1110–1114, 1992. View at Google Scholar · View at Scopus
  77. P. Stattin, O. Björ, P. Ferrari et al., “Prospective study of hyperglycemia and cancer risk,” Diabetes Care, vol. 30, no. 3, pp. 561–567, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. B. C. H. Chiu, S. M. Gapstur, P. Greenland, R. Wang, and A. Dyer, “Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 12, pp. 2348–2354, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. J. M. M. Evans, L. A. Donnelly, A. M. Emslie-Smith, D. R. Alessi, and A. D. Morris, “Metformin and reduced risk of cancer in diabetic patients,” British Medical Journal, vol. 330, no. 7503, pp. 1304–1305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. S. L. Bowker, S. R. Majumdar, P. Veugelers, and J. A. Johnson, “Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin,” Diabetes Care, vol. 29, no. 2, pp. 254–258, 2006. View at Google Scholar · View at Scopus
  81. M. Monami, C. Lamanna, D. Balzi, N. Marchionni, and E. Mannucci, “Sulphonylureas and cancer: a case-control study,” Acta Diabetologica, vol. 46, no. 4, pp. 279–284, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. E. Mannucci, M. Monami, D. Balzi et al., “Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients,” Diabetes Care, vol. 33, no. 9, pp. 1997–2003, 2010. View at Publisher · View at Google Scholar
  83. A. Dejgaard, H. Lynggaard, J. Råstam, and M. Krogsgaard Thomsen, “No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis,” Diabetologia, vol. 52, no. 12, pp. 2507–2512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. P. D. Home and P. Lagarenne, “Combined randomised controlled trial experience of malignancies in studies using insulin glargine,” Diabetologia, vol. 52, no. 12, pp. 2499–2506, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. U. X. Yang, S. Hennessy, and J. D. Lewis, “Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients,” Gastroenterology, vol. 127, no. 4, pp. 1044–1050, 2004. View at Publisher · View at Google Scholar · View at Scopus
  86. V. Donadon, M. Balbi, P. Casarin, A. Vario, and A. Alberti, “Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin,” World Journal of Gastroenterology, vol. 14, no. 37, pp. 5695–5700, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. L. G. Hemkens, U. Grouven, R. Bender et al., “Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study,” Diabetologia, vol. 52, no. 9, pp. 1732–1744, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. J. M. Jonasson, R. Ljung, M. Talbäck, B. Haglund, S. Gudbjörnsdòttir, and G. Steineck, “Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden,” Diabetologia, vol. 52, no. 9, pp. 1745–1754, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. H. M. Colhoun, “Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish diabetes research network epidemiology group,” Diabetologia, vol. 52, no. 9, pp. 1755–1765, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. C. J. Currie, C. D. Poole, and E. A. M. Gale, “The influence of glucose-lowering therapies on cancer risk in type 2 diabetes,” Diabetologia, vol. 52, no. 9, pp. 1766–1777, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Rosenstock, V. Fonseca, J. B. McGill et al., “Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study,” Diabetologia, vol. 52, no. 9, pp. 1971–1973, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. K. L. Rensing, F. M. Houttuijn Bloemendaal, E. M. Weijers et al., “Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis?” Diabetologia, vol. 53, no. 5, pp. 966–970, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. E. Liefvendahl and H. J. Arnqvist, “Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I,” Hormone and Metabolic Research, vol. 40, no. 6, pp. 369–374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. V. Donadon, M. Balbi, M. Ghersetti et al., “Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease,” World Journal of Gastroenterology, vol. 15, no. 20, pp. 2506–2511, 2009. View at Publisher · View at Google Scholar · View at Scopus
  95. D. Weinstein, M. Simon, E. Yehezkel, Z. Laron, and H. Werner, “Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells,” Diabetes/Metabolism Research and Reviews, vol. 25, no. 1, pp. 41–49, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Shukla, J. Grisouard, V. Ehemann, A. Hermani, H. Enzmann, and D. Mayer, “Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines,” Endocrine-Related Cancer, vol. 16, no. 2, pp. 429–441, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Mayer, A. Shukla, and H. Enzmann, “Proliferative effects of insulin analogues on mammary epithelial cells,” Archives of Physiology and Biochemistry, vol. 114, no. 1, pp. 38–44, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. S. L. Bowker, Y. Yasui, P. Veugelers, and J. A. Johnson, “Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure,” Diabetologia, vol. 53, no. 8, pp. 1631–1637, 2010. View at Publisher · View at Google Scholar
  99. P. D. Home, S. E. Kahn, N. P. Jones, D. Noronha, H. Beck-Nielsen, and G. Viberti, “Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials,” Diabetologia, vol. 53, no. 9, pp. 1838–1845, 2010. View at Publisher · View at Google Scholar
  100. J. M. M. Evans, S. A. Ogston, A. Emslie-Smith, and A. D. Morris, “Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin,” Diabetologia, vol. 49, no. 5, pp. 930–936, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. G. Libby, L. A. Donnelly, P. T. Donnan, D. R. Alessi, A. D. Morris, and J. M. M. Evans, “New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes,” Diabetes Care, vol. 32, no. 9, pp. 1620–1625, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. A. DeCensi, M. Puntoni, P. Goodwin et al., “Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis,” Cancer Prevention Research, vol. 3, no. 11, pp. 1451–1461, 2010. View at Publisher · View at Google Scholar
  103. V. N. Anisimov, L. M. Berstein, P. A. Egormin et al., “Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice,” Experimental Gerontology, vol. 40, no. 8-9, pp. 685–693, 2005. View at Publisher · View at Google Scholar · View at Scopus
  104. V. N. Anisimov, P. A. Egormin, T. S. Piskunova et al., “Metformin extends life span of HeR-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo,” Cell Cycle, vol. 9, no. 1, pp. 188–197, 2010. View at Google Scholar · View at Scopus
  105. L. A. Cantrell, C. Zhou, A. Mendivil, K. M. Malloy, P. A. Gehrig, and V. L. Bae-Jump, “Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy,” Gynecologic Oncology, vol. 116, no. 1, pp. 92–98, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. E. Rozengurt, J. Sinnett-Smith, and K. Kisfalvi, “Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer,” Clinical Cancer Research, vol. 16, no. 9, pp. 2505–2511, 2010. View at Publisher · View at Google Scholar
  107. A. Tomimoto, H. Endo, M. Sugiyama et al., “Metformin suppresses intestinal polyp growth in Apc mice,” Cancer Science, vol. 99, no. 11, pp. 2136–2141, 2008. View at Publisher · View at Google Scholar · View at Scopus
  108. Y. Zhuang and W. K. Keith, “Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27 or p21,” Journal of Molecular Signaling, vol. 3, article 18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. A. Majuri, M. Santaniemi, A. Kunnari et al., “Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study,” European Journal of Endocrinology, vol. 156, no. 2, pp. 263–269, 2007. View at Publisher · View at Google Scholar
  110. S. K. Vijay, M. Mishra, H. Kumar, and K. Tripathi, “Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes,” Acta Diabetologica, vol. 46, no. 1, pp. 27–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. M. Monami, C. Lamanna, N. Marchionni, and E. Mannucci, “Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials,” Diabetes Care, vol. 31, no. 7, pp. 1455–1460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  112. W. L. Read, M. Q. Baggstrom, P. M. Fracasso, and R. Govindan, “A phase I study of bexarotene and rosiglitazone in patients with refractory cancers,” Chemotherapy, vol. 54, no. 3, pp. 236–241, 2008. View at Publisher · View at Google Scholar · View at Scopus
  113. G. A. Weaver, C. T. Tangel, J. A. Krause et al., “Biomarkers of human colonic cell growth are influenced differently by a history of colonic neoplasia and the consumption of acarbose,” Journal of Nutrition, vol. 130, no. 11, pp. 2718–2725, 2000. View at Google Scholar · View at Scopus
  114. T. Vilsbøll, “The effects of glucagon-like peptide-1 on the beta cell,” Diabetes, Obesity and Metabolism, vol. 11, supplement 3, pp. 11–18, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. T. Salvatore, O. Carbonara, D. Cozzolino, R. Torella, and F. C. Sasso, “Progress in the oral treatment of type 2 diabetes: update on DPP-IV inhibitors,” Current Diabetes Reviews, vol. 5, no. 2, pp. 92–101, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. T. Stulc and A. Sedo, “Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects?” Diabetes Research and Clinical Practice, vol. 88, no. 2, pp. 125–131, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. J. A. Koehler and D. J. Drucker, “Activation of glucagon-like peptide-1 receptor signaling does not modify the growth or apoptosis of human pancreatic cancer cells,” Diabetes, vol. 55, no. 5, pp. 1369–1379, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. L. B. Knudsen, L. W. Madsen, S. Andersen et al., “Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation,” Endocrinology, vol. 151, no. 4, pp. 1473–1486, 2010. View at Publisher · View at Google Scholar · View at Scopus